Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine

International Journal of Neuropsychopharmacology

Volumn 21, Issue 1, 2018, Pages 84-88

  Shirayama, Yukihiko ^a   Hashimoto, Kenji ^a,b  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

(R) ketamine; (R) norketamine (2R,6R) hydroxynorketamine; learned helplessness; metabolism

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG METABOLITE; HYDROXYNORKETAMINE; KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; HYDROXYNORSPERMIDINE; SPERMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CONDITIONED AVOIDANCE RESPONSE TEST; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; LEARNED HELPLESSNESS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; CHEMISTRY; DISEASE MODEL; OFF LABEL DRUG USE; TIME FACTOR;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HELPLESSNESS, LEARNED; KETAMINE; MALE; OFF-LABEL USE; RATS; SPERMIDINE; TIME FACTORS;

EID: 85041230967     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyx108     Document Type: Article

References (24)

1. Abdallah CG (2017) What's the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise? Biol Psychiatry 81: 61-63.
2. Desta Z, Moaddel R, Ogburn ET, Xu C, Ramamoorthy A, Venkata SL, Sanghvi M, Goldberg ME, Torjman MC, Wainer IW (2012) Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica 42: 1076-1087.
3. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113: 678-684
4. Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22: 238-249.
5. Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, Aghajanian GK, Duman RS (2015) Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. Proc Natl Acad Sci USA 112: 8106-8111.
6. Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 361: 9-16.
7. Hashimoto K (2016a) R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46: 2449-2451.
8. Hashimoto K (2016b) Ketamine's antidepressant action: beyond NMDA receptor inhibition. Expert Opin Ther Targets 20: 1389-1392.
9. Hashimoto K (2017) Rapid antidepressant activity of ketamine beyond NMDA receptor. In: The NMDA Receptors (Hashimoto K, ed), pp 69-81. New York: Humana Press.
10. Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267: 173-176.
11. Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30: 853-858.
12. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46: 1459-1472.
13. Monteggia LM, Zarate C Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30: 139-143.
14. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172: 950-966.
15. Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267: 177-182.
16. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25: 2449-2458.
17. Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT (2009) Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 37: 1769-1778.
18. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5: 632.
19. Yang C, Han M, Zhang JC, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatric Res 239: 281-283.
20. Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R, 6R)-hydroxynorketamine. Biol Psychiatry 82: 43-44.
21. Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83: 18-28.
22. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDARindependent antidepressant actions of ketamine metabolites. Nature 533: 481-486.
23. Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, Zarate CA Jr, Mager DE, Wainer IW (2012) Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 74: 304-314.
24. Zhang JC, Li SX, Hashimoto K (2014) R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116: 137-141.